SKI Market

Indian Indices

Sensex

83,570.35 187.64
( 0.23%)

Global Indices

Nasdaq

49,379.59 -83.86
(-0.17%)

Dow Jones

6,960.70 -4.77
(-0.07%)

Hang Seng

53,996.71 -113.79
(-0.21%)

Nikkei 225

10,219.48 -19.46
(-0.19%)

Forex

USD-INR

90.32 0.07
(0.08%)

EUR-INR

104.98 -0.13
(-0.12%)

GBP-INR

121.10 -0.20
(-0.16%)

JPY-INR

0.57 0.00
(0.21%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Marksans Pharma Ltd

Industry : Pharmaceuticals - Indian - Formulations

BSE Code

ISIN Demat

Book Value()

524404

INE750C01026

32.9918134

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

MARKSANS

32.38

7805.75

EPS(TTM)

Face Value()

Div & Yield %

5.32

0.46

Back

Mefcom Capital Markets consolidated net profit rises 496.43% in the June 2025 quarter

Aug 14,2025

Net profit of Mefcom Capital Markets rose 496.43% to Rs 5.01 crore in the quarter ended June 2025 as against Rs 0.84 crore during the previous quarter ended June 2024. Sales rose 16.71% to Rs 48.97 crore in the quarter ended June 2025 as against Rs 41.96 crore during the previous quarter ended June 2024.

Particulars	Quarter Ended
	Jun. 2025	Jun. 2024	% Var.
Sales	48.97	41.96	17
OPM %	10.80	2.26	-
PBDT	5.10	0.93	448
PBT	5.08	0.91	458
NP	5.01	0.84	496

83,570.35 187.64 ( 0.23%)

49,379.59 -83.86 (-0.17%)

6,960.70 -4.77 (-0.07%)

53,996.71 -113.79 (-0.21%)

10,219.48 -19.46 (-0.19%)

90.32 0.07 (0.08%)

104.98 -0.13 (-0.12%)

121.10 -0.20 (-0.16%)

0.57 0.00 (0.21%)